Mission
TO PROVIDE GRANTS TO SECTION 501C3 ORGANIZATIONS THAT ADVANCE AND IMPROVE SCIENTIFIC RESEARCH IN IMMUNOTHERAPY AND TO ORGANIZATIONS THAT PROMOTE, ADVANCE AND IMPROVE EDUCATION AND SUPPORT CANCER PATIENTS
Based in Flemington, NJ, The National Immunotherapy Cancer operates as a Public Charity. The organization reported $390K in revenue, $100K in expenses, $1.2M in total assets for fiscal year 2024. Imperigo tracks 2 reported grant relationships connected to this organization totaling approximately $12K.
TO PROVIDE GRANTS TO SECTION 501C3 ORGANIZATIONS THAT ADVANCE AND IMPROVE SCIENTIFIC RESEARCH IN IMMUNOTHERAPY AND TO ORGANIZATIONS THAT PROMOTE, ADVANCE AND IMPROVE EDUCATION AND SUPPORT CANCER PATIENTS
How The National Immunotherapy Cancer divides every $100 it spends, from its own Form 990 filings, averaged across 8 years.
No fundraising costs are reported. That often means fundraising runs through a separate affiliated organization that files its own return.
Source: Form 990 filings with the IRS, latest fiscal year 2024. Shares are from the organization's reported expenses. Data by Imperigo; not affiliated with the IRS.
Showing up to 5 of 2 total records — full history available with membership.
Officer compensation and complete director data available with membership.
| Year | Revenue | Expenses | Assets |
|---|---|---|---|
| 2024 | $390K | $100K | $1.2M |
| 2023 | $151K | $98K | $1.1M |
| 2022 | $4K | $136K | $1.1M |
| 2021 | $6K | $78K | $1.4M |
| 2020 | $14K | $1.0M | $1.6M |
Between 2020 and 2024, reported annual revenue grew from $14K to $390K (+2693%), with total assets most recently reported at $1.2M.
Interactive year-over-year charts and full filing details available with membership.